WellMedr review: the compounded price is behind a date-of-birth field

For the two branded drugs, $1,399 a month for Ozempic and $1,599 for Zepbound, both stated as month-to-month plans on its own weight-loss page. For everything it compounds — which is most of what it sells — the honest answer is that WellMedr does not say. Its product pages carry no price, its Shopify product feed returns $0.00 for every weight-loss variant, and its eligibility funnel showed no figure across the four screens reachable before it asked for a date of birth on August 10, 2026.

They are the numbers WellMedr leads with, and they sit beside larger ones on the same card. The tirzepatide card reads "Monthly Plan $399" struck through, "$299/ today", and "Starting At $99 a month"; the semaglutide card reads "$299" struck through, "$199/ today", and "Starting At $59 a month". A site-wide banner then offers "$200 OFF Every Month… For Life" and a footer panel offers "$150 off for Life". Those frames do not reconcile, and no page states which one applies to a second charge. That is why no compounded price is filed on this review.

No. Both compounded plans state "Shipped every 4 weeks", and a four-weekly cycle bills 13 times a year rather than 12. Whatever the per-cycle figure turns out to be, multiply it by 13 for the annual cost, not 12 — on a nominal "$99 a month" that is about $1,287 a year instead of $1,188. The two branded plans are described as month-to-month, so those are 12.

Four screens. "Check Eligibility" hands off to intake.wellmedr.com, which embeds a hosted form. It asks height and weight, then computes a BMI and tells you whether you can continue, then asks a goal weight, then sex, then date of birth. No price appears at any point before that. We stopped at the birth date and entered nothing identifying.

For the branded products, yes — "Contains Semaglutide" and "Contains Tirzepatide" are printed on the cards. For the compounded line, no. The products are titled "Compounded GLP-1" and "Compounded GLP-1/GIP", the descriptions never name the molecule, and the only place it appears is the URL: `/products/injectable-semaglutide` and `/products/injectable-tirzepatide`.

It does not say. There is no pharmacy name anywhere on the site, no street address, and no compounding category — neither 503A nor 503B is mentioned. The assurances offered are "accredited pharmacies", which names no accrediting body, and a banner reading "FDA-regulated pharmacies", which is not what either kind of compounding pharmacy is: 503A pharmacies are licensed and inspected by state boards, and 503B outsourcing facilities register with FDA rather than being regulated by it in the sense the phrase suggests.

It is a verified one, which is not the same thing. Novo Nordisk and Eli Lilly both operate direct cash-pay channels for these products at well under what WellMedr charges, and a prescription written by any telehealth clinician can be filled through them. The figures are on this page because WellMedr publishes them plainly and month-to-month — the one part of its pricing that needs no interpretation — not because they are competitive.

No. FDA's live warning-letter index was queried on August 10, 2026 for "wellmedr" and for the spaced variant "well medr", each returning its full result set. "wellmedr" returned nothing. "well medr" returned two rows, but their company columns read Sun Pharmaceutical Industries Ltd. and US Specialty Formulations, LLC — the phrase matched inside letter bodies, and neither is this company. A query for "skinnyrx" in the same pass returned that company's February 2026 letter, which is what makes the zeros meaningful rather than a sign of a broken search.